Difference between revisions of "Vinblastine (Velban)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 22: Line 22:
 
*[[Non-small cell lung cancer]]
 
*[[Non-small cell lung cancer]]
 
*[[Testicular cancer]]
 
*[[Testicular cancer]]
 +
 +
==History of changes in FDA indication==
 +
11/25/1965: Initial approval
  
 
==Also known as==
 
==Also known as==
Line 54: Line 57:
 
|-
 
|-
 
|}
 
|}
 +
 
==References==
 
==References==
 
<references/>
 
<references/>

Revision as of 02:46, 30 November 2020

General information

Class/mechanism: Vinca alkaloid, inhibits microtubule formation in the mitotic spindle, causing cell cycle arrest in metaphase.[1][2]
Route: IV
Extravasation: vesicant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Patient drug information

Diseases for which it is used

History of changes in FDA indication

11/25/1965: Initial approval

Also known as

  • Generic names: chlorhexamide, vinblastine sulfate, vinblastine sulphate, vincaleukoblastine, VLB
  • Brand names:
Synonyms
Alkaban-AQ Blastovin Cellblastin Cytoblastine Erbablas
Exal Faulblastina Lemblastine Periblastine Rabinefil
Velban Velbastine Velbe Vinblasin Vinblastin
Vinblastina

References